336 related articles for article (PubMed ID: 33254040)
1. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
3. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Liu Y; Meng J; Wang G
Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials.
Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B
J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials.
Sun W; Li J; Zhang Z; Su X
J Clin Pharm Ther; 2021 Apr; 46(2):241-255. PubMed ID: 33135237
[TBL] [Abstract][Full Text] [Related]
7. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
Zhou S; Jiang Y; Luo C; Yuan L
Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
[TBL] [Abstract][Full Text] [Related]
8. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Staropoli N; Ciliberto D; Del Giudice T; Iuliano E; Cucè M; Grillone F; Salvino A; Barbieri V; Russo A; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2018 Nov; 131():83-89. PubMed ID: 30293710
[TBL] [Abstract][Full Text] [Related]
9. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
[TBL] [Abstract][Full Text] [Related]
10. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Onstad M; Coleman RL; Westin SN
Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Wei Y; He L; Liu T; Guo T; Xie C; Jia J; Lin Y; Liu J; Fan J
Front Pharmacol; 2024; 15():1372077. PubMed ID: 38584601
[No Abstract] [Full Text] [Related]
13. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Cheng H; Yang J; Liu H; Xiang Y
Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
Yang Y; Du N; Xie L; Jiang J; Mo J; Hong J; Mao D; Ng DM; Shi H
World J Surg Oncol; 2020 Jul; 18(1):151. PubMed ID: 32622363
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
Sun X; Wang X; Zhang J; Zhao Z; Feng X; Liu L; Ma Z
Breast; 2021 Dec; 60():26-34. PubMed ID: 34455227
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
[TBL] [Abstract][Full Text] [Related]
19. Role of PARP inhibitors beyond BRCA mutation and platinum sensitivity in epithelial ovarian cancer: a meta-analysis of hazard ratios from randomized clinical trials.
Purwar R; Ranjan R; Pal M; Upadhyay SK; Kumar T; Pandey M
World J Surg Oncol; 2023 May; 21(1):157. PubMed ID: 37217940
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
Peters ITA; Marchetti C; De Palma A; Giannarelli D; Carcagnì A; Scambia G; Fagotti A
Eur J Cancer; 2023 Jul; 187():77-86. PubMed ID: 37130463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
